Parabilis Medicines filed for an IPO days after signing a wide oncology collaboration with Regeneron, aiming to fund Phase 3 development of its Wnt/β-catenin pathway inhibitor zolucatetide for desmoid tumors. The IPO plan follows reported early clinical results, FDA fast-track designation, and a deal structure that includes upfront Regeneron payments and equity investment tied to future development milestones.